Gilead Sciences, Inc. (FRA:GIS)
96.13
+0.93 (0.98%)
At close: Sep 29, 2025
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.08B USD in the quarter ending June 30, 2025, with 1.84% growth. This brings the company's revenue in the last twelve months to $28.86B, up 3.81% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.86B
Revenue Growth
+3.81%
P/S Ratio
4.85
Revenue / Employee
$1.64M
Employees
17,600
Market Cap
119.11B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Rheinmetall AG | 10.67B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Gilead Sciences News
- 12 days ago - May 2026 Options Now Available For Gilead Sciences (GILD) - Nasdaq
- 13 days ago - Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management - Wallstreet:Online
- 13 days ago - Fangzhou Wins Gilead ‘Award of Excellence' for AI-Driven Chronic Disease Management - GlobeNewsWire
- 13 days ago - GILD Partners with Nurix for Potential IRAK4 Protein Degrader - GuruFocus
- 14 days ago - Insider Sell: Johanna Mercier Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus
- 14 days ago - QQQM, GOOGL, ADBE, GILD: Large Inflows Detected at ETF - Nasdaq
- 14 days ago - GILD: JP Morgan Raises Price Target, Reaffirms Overweight Rating | GILD Stock News - GuruFocus
- 15 days ago - Validea Detailed Fundamental Analysis - GILD - Nasdaq